A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.
Also called NCT03170518
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 171 participants
- Registry
-
NCT03170518 -
2016-005223-88
-
- Other papers using this trial's data
- Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, China, Greece, India, Malaysia, Mexico, Philippines, Poland, Russia
- Registry status
- Completed
Technical summary
Registry record NCT03170518. Randomized; double masking; primary purpose treatment. Start 2017-07-21 (actual); primary completion 2023-09-20 (actual). Results posted on 2025-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin 100 mg
- Intervention (Drug)
- Canagliflozin 300 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct03170518- Content hash
3770c3c4018cddf431cef200c542bf9c7f8b460ed5deddbf8abebcb66d9b59ed